Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphataemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Colestilan (Primary)
- Indications Hyperphosphataemia
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 31 Mar 2014 New trial record
- 30 Nov 2009
- 01 Jun 2009